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ABSTRACT 
90% of drugs being researched today, posses poor solubility setback which inturn renders  the drug with slower rate of absorption from the 
buccal route; hence dissolution is the rate limiting step for such lipophilic drugs. So, there is a need to keep a check on the dissolution profile of 
these drugs to ensure maximum therapeutic utilization. The dissolution rate therefore becomes a primary factor which governs the rate and 
extent of its absorption. Enormous work is being performed in the field of enhancement of solubility and dissolution behaviour of such drugs. 
Advancements and innovations have developed solid dispersion (SD) technique as the novel method for the solubility enhancement. Precision of 
dosing and patient's compliance is a crucial prerequisite for the management of chronic Antihypertensive treatment, So there arised a need to 
formulate a system which should resolve the difficulties associated with conventional tablets. This issue can be better tackled with the 
formulation of orally fast disintegrating tablets. The aim of the present study was to improve the solubility and dissolution rate of Lercanidipine 
hydrochloride (LRH) by formulating a solid dispersion with Polyvinyl pyrollidine (PVP-K30) and Guargum. Full Factorial designs are exploited to 
learn and research the effects of different variables on the quality determinant parameters. An appropriate statistical model was selected for the 
scrutiny of the enhanced dissolution pattern. Finally, these solid dispersions were incorporated into fast disintegrating tablets. 
Keywords: Lercanidipine Hydrochloride, Solid dispersion, Statistical design approach, Melt fusion method, Fast disintegrating tablet, In vivo 
studies 
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INTRODUCTION 
Due to the ongoing technological advancements in the 
pharma world of designing various drug delivery systems. 
Majority drug molecules display poor solubility, which in 
turn affects the overall bioavailability of the molecule1. When 
dissolution is rate limited, the buccal delivery of such drug 
candidates is a tedious task2. There are number of 
methodologies which can be targetted for solubility 
enhancement, such as salt formation, use of cosolvents, 
particle size reduction, inclusion complexes of cyclodextrins  
etc3-12. Above all these, fabrication of solid dispersions can 
serve both the purposes of solubility and dissolution 
enhancement. These systems have aced in the domain of 
solubility enhancement, as they surpass the obstacles of the 
ancient methods. But the real success depends on the carrier 
selection and its optimization. When such systems come in 
contact with water, carrier is eroded and drug is set free as a 
fine colloidal dispersion with exorbitant surface area 
rendering elevated rates of drug dissolution and biological 
availability. In relation to all above, a modification from 
crystallin to amorphous form takes place, which is valuable 
as dissolution of an amorphous drug is simple and do not  
need any energy to fragment the crystalline structure13,14. 
Lercanidipine hydrochloride chemically is 2[(3,3-
diphenylpropyl) (methyl)amino]-1, 1-imethylethyl methyl 
2,6- dimethyl-4- (3-nitrophenyl)-1, 4-dihydropyridine-3, 5-
dicarboxylate hydrochloride. It is reported in 1, 4-
dihydropyridine calcium channel blockers pharmacological 
class15. It is a BCS class II drug with low aqueous solubility 
and bioavailability. So improvement of the drug 
bioavailability and therapeutic efficacy is a crucial parameter 
which can only be achieved by increasing the solubility. The 
main goal is to work on the solubility enhancement by 
dispersing the drug in the polymer matrix of PVP and Guar 
Gum in different ratios. Melt fusion method is used for the 
preparation of solid dispersion and preliminary screening 
for polymer selection is performed. As oral route being the 
most suitable route of administration has become a vital 
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component nowadays, so work has been undertaken to 
develop a fast dissolving system, which disintegrates and 
disperses the drug in few seconds and can be conveniently 
administered. Finally, these solid dispersions were 
incorporated into fast disintegrating tablets which were 
further evaluated. 
MATERIALS  
Lercanidipine hydrochrloride was received as a free gift 
sample from Torrent Pharmaceutical Pvt. Limited, Baddi, 
Himachal Pradesh, India. Polyvinyl pyrollidine (PVP-K30) 
and Guar Gum was purchased from local vendor. Other 
materials used were of analytical grade.  
EXPERIMENTAL 
Solubility study 
Solubility studies of lercanidipine hydrochloride were 
checked in water, phosphate buffer pH 6.8, HCl buffer pH 1.2 
and phosphate buffer pH 7.2. The saturated solutions were 
prepared by adding excess drug in the solvent system. The 
solvent system was shaken for 48 hrs at 250C. Filtered the 
solutions through a 0.42 Millipore filter. Samples were 
analysed by UV spectrophotometer 236 nm. The solubility 
data is reported in table 116.  
Table 1: Solubility of lercanidipine HCl in various solvent 
Solvents Solubility (mg/ml) 
Water 0.014±0.002 
Phosphate buffer pH 6.8 0.005±0.001 
0.1 N HCl 0.160±0.012 
Phosphate buffer pH 7.4 0.004±0.015 
 
Preliminary attempts for the screening of polymers for 
solid dispersion preparation 
The success of a solid dispersion system is rooted on the 
type and concentration of polymer. Various polymers were 
scrutinized for the enhancement of solubility. Solid 
dispersions were prepared with melt fusion method. Drug 
was mixed with Polyvinyl pyrollidine (PVP K-30) (LS-1 to LS-
3) and Guar Gum (LS-4 to LS-6)  in various ratios.  The melt 
was evaporated in a water bath at 70◦C. Then immediately 
solidified the mixture in ice bath with uninterrupted 
stirring17,18. 
Evaluation of Solid dispersions  
Solubility studies  
The solubility study of various Solid dispersions batches was 
determined in phosphate buffer pH 6.8. Weighed amount of 
solid dispersion equivalent to drug dose was added in excess 
quantity of solvent in screw-capped glass vials. The vials 
were continuously shaken for 2 hours. Finally the solutions 
were filtered and analysed spectrophotometrically at 236 
nm. 
Table 2: Solubility data of preliminary solid dispersion 
batches 
Formulation Code Solubility (mg/ml) 
LS-1 0.347±0.08 
LS-2 0.655±0.01 
LS-3 0.801±0.07 
LS-4 0.878±0.01 
LS-5 0.941±0.08 
LS-6 0.798±0.09 
Infra red Spectral analysis  
FT-IR spectrum of pure Lercanidipine hydrochloride and 
batch LS-5 is shown in Figure 1 and Figure 2 respectively. 
The IR spectra of Lercanidipine hydrochloride exhibited 
distinctive peaks at 3443 cm-1 stretching, 1649 cm-1 Amides 
(RCONH2), 1521 cm-1 Aromatics (C-C ring). The FTIR 
spectra of LS-5 displayed same characteristic peaks which 
also reveals that the drug and excipients used in the 
formulation are stable and posses no interaction19,20.
 
 
Figure 1: FTIR Spectra of Lercanidipine Hydrochloride 
 
Figure 2: FTIR Spectra of batch LS-5 
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Differential scanning calorimetry  
The DSC studies were conducted using DSC-60 instrument 
(Schimadzu corporation Japan). The samples of pure drug 
and batch LS-5 were sealed and heated at a constant rate at 
50ºC/min over a temperature range of 25-175oC. Inert 
atmosphere was created by introducing nitrogen gas at 50 
ml/mins flow rate21,22. DSC thermographs melting 
endothermic at 179.70C (1720C-1830C) at 88.97 J/g i.e. 
melting point and crystalline state of drug. DSC thermograph 
of LS-5 is shown in Figure 4 which shows no peak i.e. melting 
point and amorphous state of drug. Disappearance of the 
drug melting peak confirmed that amorphization had 
occured.
 
 
Figure 3: DSC of Lercanidipine hydrochloride 
 
Figure 4: DSC of batch LS-5 
 
Scanning electron microscopy  
The drug and batch LS-5 were examined for surface 
changes using scanning electron microscope as shown in 
figure 5 and figure 6 respectively. Finally surface 
topography was studied23. 
 
 
Figure 5: SEM image of the Lercanidipine Hydrochloride 
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Figure 6: SEM image of batch LS-5 
 
Experimental Design 
A three- level, two factor experimental design was choosen 
for the study as shown in Table 3. The table indicates the 
ratios of independent variables, Lercanidipine Hydrochloride 
(A) and screened polymer Guar gum (B). The solubility and 
drug content, was selected as dependent variables. Response 
surface methodology computations were performed using 
Design Expert Software version 11. Polynomial models 
including interaction and quadratic terms were generated 
for all the response variables using multiple linear 
regression analysis approach. In addition contour and 
surface plots were also obtained to represent the effect of 
independent variables graphically. 
Preparation of Lercanidine Hydrochloride Fast 
disintegrating Tablets containing superdisintegrants  
Different batches of fast disintegrating tablets of 
Lercanidipine hydrochloride containing best optimized solid 
dispersion batch (OLS-1) were prepared according to the 
proportions given in Table 3. Powdered solid dispersion 
batch (OLS-1) equivalent to 10 mg of LR, was mixed with 
other excipients. Finally tablets were compressed on a rotary 
punch tablet machine (Karnavati, Mumbai, India) keeping 
final weight of the tablet (100 mg) 24,25. 
 
Table 3: Optimization parameters of Guargum loaded solid dispersion 
Run Dependent variables Independent variables 
Factor 1 Factor 2 Response 1 Response 2 
A:Drug conc.(mg) B:Polymer conc.(mg) Solubility(µg/ml) 
% drug release in 60 
mins(%) 
OLS-1 300 400 0.941 98 
OLS-2 441.421 400 0.88 98 
OLS-3 300 682.843 0.941 85 
OLS-4 200 200 0.789 80 
OLS-5 158.579 400 0.699 98 
OLS-6 400 200 0.87 80 
OLS-7 400 600 0.87 87 
OLS-8 300 117.157 0.941 63 
OLS-9 200 600 0.789 87 
 
Table 4: ANOVA for Quadratic model Response 1: Solubility 
Source 
Sum of 
Squares 
df 
Mean 
Square 
F-value p-value 
Model 0.0718 5 0.0144 27.45 0.0002(Significant) 
A-Drug conc. 0.0218 1 0.0218 41.77 0.0003 
B-Polymer 
conc. 
1.388E-17 1 1.388E-17 2.654E-14 1.0000 
AB 0.0000 1 0.0000 0.0000 1.0000 
A² 0.0499 1 0.0499 95.42 < 0.0001 
B² 0.0006 1 0.0006 1.06 0.3369 
Residual 0.0037 7 0.0005   
Lack of Fit 0.0037 3 0.0012   
Pure Error 0.0000 4 0.0000   
Cor Total 0.0754 12    
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Table 5: ANOVA for Quadratic model Response 2: Drug content 
Source 
Sum of 
Squares 
df 
Mean 
Square 
F-value p-value 
Model 1370.59 5 274.12 39.08 < 0.0001(Significant) 
A-Drug conc. 0.0000 1 0.0000 0.0000 1.0000 
B-Polymer conc. 254.39 1 254.39 36.26 0.0005 
AB 0.0000 1 0.0000 0.0000 1.0000 
A² 2.72 1 2.72 0.3874 0.5534 
B² 1108.80 1 1108.80 158.06 < 0.0001 
Residual 49.11 7 7.02   
Lack of Fit 49.11 3 16.37   
Pure Error 0.0000 4 0.0000   
Cor Total 1419.69 12    
 
 
Table 6: Composition of Fast Disintegrating Tablet 
Formulation Code Ingredients in mg 
 
LT-1 LT-2 LT-3 LT-4 LT-5 LT-6 
LS equivalent to 10 mg 50 50 50 50 50 50 
Crosspovidone 2 4 6 - - - 
Croscarmellose - - - 2 4 6 
Avicel pH 102 45 43 41 45 43 41 
Magnesium stearate 1 1 1 1 1 1 
Talc 2 2 2 2 2 2 
Total weight  100 100 100 100 100 100 
 
Pre compression parameters  
Angle of repose: Accurately weighed quantity of the powder 
mixture was allowed to freely flow on to a surface from the 
funnel fixed at an appropriate height. The diameter is noted 
down. Finally angle of repose was calculated by using the 
following equation.  
Tan θ = h/r                                                                                 (1)  
Where θ is angle of repose, h is height of the cone and r is 
radius of the cone base.  
Bulk density: Accurately weighed quantity of blend was 
added to a graduated cylinder and the bulk volume was 
measured using equation 2.  
Bulk density = weight of the powder / bulk volume      (2)  
Tapped density: Accurately weighed quantity of blend was 
added to  a graduated cylinder and the bulk volume was 
measured using equation 3.  
Tapped density = weight of the blend / final volume         (3)          
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Compressibility index: The compressibility index (Carr’s 
index) indicates the property of a powder to be compressed 
and can be calculated using equation 4.  
Carr’s compressibility index =  
[(Tapped density- bulk density/tapped density)] × 100        (4)  
 
Table 7: Data for Precompression parameters 
Formulation 
Code 
Angle of Repose(º) Bulk Density(g/cc3) Tapped Density 
(g/cc3) 
Compressibility 
Index (%) 
LT-1 23.7±0.14 0.42±0.12 0.58±0.17 27.58±0.18 
LT-2 24.7±0.02 0.41±0.15 0.66±0.05 37.87±0.61 
LT-3 24.8±0.08 0.43±0.08 0.55±0.09 21.81±0.09 
LT-4 23.2±0.15 0.51±0.07 0.65±0.18 22.95±0.07 
LT-5 23.1±0.20 0.45±0.71 0.59±0.23 23.72±0.15 
LT-6 22.8±0.02 0.44±0.45 0.62±0.05 32.25±0.21 
 
Post compression parameters  
Evaluation of Fast Disintegrating Tablets 
The tablet batches were evaluated for weight variation, 
friability, hardness, thickness, uniformity of weight, 
disintegration time, wetting time, drug content and in vitro 
dissolution study. 
Weight variation 
Average weight of 20 tablets was determined and then the 
individual tablet weight was compared with average weight 
as shown in table 8. 
Friability 
The tablets were weighed (Winitial) and placed in friabilator 
(Biolinkz, India). The appratus was operated at 25rpm for 4 
minutes. Finally the tablets were dedusted and weighed 
again (Wfinal). The data is reported in table 8.  
F = Winitial -Wfinal x 100                    (5) 
               Wfinal 
Hardness 
Pfizer Hardness tester was used to check the hardness 
expressed in kg/cm2. The data is shown in table 8. 
Wetting time 
For the determination of wetting time, tissue paper was 
soaked with 10 ml of water. Tablet was kept over the wet 
surface and noted down the time required for water to  reach 
at the top of the tablet. The data is reported in table 8. 
Disintegration Test 
The Disintegration test apparatus was used to calculate the 
disintegration time and data is reported in table 8.  
Determination of drug content  
Ten tablets were powdered and the blend equivalent to 10 
mg of LR was weighed and dissolved in phophate buffer pH 
6.8. The solution was then filtered, diluted and drug content 
was determined by spectrophotometer at 236 nm26-28. The 
data is recorded in table 8. 
 
Table 8: Data for the post compression parameters 
Batch Weight 
variation(mg) 
Friability 
    (%) 
Hardness 
(Kg/cm2) 
Wetting 
time(Sec) 
Disintegration 
time(Sec) 
Drug content 
(%) 
LT-1 99.1±0.39 0.62±0.87 2.8±0.21 44±0.81 55±0.18 98±0.91 
LT-2 98.4±0.78 0.77±0.55 2.5±0.76 37±0.77 45±0.33 99±0.87 
LT-3 99.8±0.55 0.75±0.49 2.9±0.86 25±0.52 37±0.56 99±0.11 
LT-4 99.3±0.37 0.88±0.99 3.0±0.12 35±0.28 47±0.61 98±0.37 
LT-5 99.3±0.84 0.85±0.89 2.3±0.11 26±0.34 40±0.37 99±0.27 
LT-6 99.4±0.86 0.71±0.77 2.2±0.85 19±0.43 30±0.81 99±0.71 
 
In-vitro dissolution study 
Dissolution studies were conducted in a beaker having 30 ml 
phosphate buffer pH 6.8 which was maintained at 37 ± 0.50 
°C. The assembly was placed on a magnetic stirrer and 
samples were drawn at appropriate time periods with 
replacement. The aliquots were filtered, diluted and 
analyzed by spectrophotometerically at 236nm29. 
In vivo study deign study 
The in vivo study procedure (Protocol approval number: 
RIP/IAEC/2018-19/02) was approved by the Institutional 
Animal Ethics Committee. Male rabbits (New Zealand) were 
choosen for the pharmacokinetic data collection. Rabbits 
(weighing 2.6–3.1 kg) were fasted overnight before the study 
plan proceeded. Divided the rabbits into two groups. One 
group received the marketed formulation (Lercanidipine 
hydrochloride equivalent to 3 mg/kg) whereas the other 
group received optimized fast disintegrating tablet batch LT-
6. Tablet to be tested was kept on the tongue of the rabbit. 
This has been achieved with the help of body restraint 
device. Initially the mouth was wetted with water and then 
tablet was placed on the tongue30-32. Blood samples were 
withdrawn from the peripheral vein of each rabbit at 
appropriate interval of 0, 1, 2, 3, 4, 5, 7, 9, 12, 24 hrs. 
The samples were centrifuged at 2000 rpm for 20 min. The 
clear supernatant serum layer was harvested and stored at -
40 °C. Frozen samples were thawed at ambient temperature 
(25±2 °C) for at least 60 m. Serum samples were 
appropriately diluted  with acetonitrile, vortexed and finally 
centrifuged again. Mixed Lercanidipine HCl with protein free 
plasma. From this 20μl was injected into an isocratic HPLC 
with UV detector. The column employed for the study was 
C18 (250 x 4.6mm, particle size: 5μm, High pressure 
gradient, Detector : UV Wavelength:240nm). Potassium 
dihydrogen orthophosphate: ACN pH 4(40:60) was used as 
mobile phase with a flow rate upto 1.0 ml/min. Various 
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pharmacokinetic parameters such as peak plasma 
concentration (Cmax), the time at which peak occurred 
(tmax) and area under the curve (AUC) were computed from 
time v/s serum drug concentration values. 
 
 
Figure 8: Dissolution release profile of FDT Tablet batches (LT-1 to LT-6) 
 
Table 9: Pharmacokinetic parameters following after oral administration. 
Pharmacokinetic parameters Optimized Formulation LT-6 Marketed Preparation 
Cmax 20.11 16.31 
Tmax 3hr 4hr 
AUC 230 205 
 
 
Figure 9: The pharmacokinetic profile of optimized FDT and marketed product. 
 
Stability Studies  
The best formulation batch was charged for the stability 
study as per ICH guidelines.  They were performed at 
temperature of 40+20C / 75% RH for 3 months. LT-6 batch 
was charged for the study. It was wrapped in a butter paper 
followed by aluminum foil and sealed in an air-tight plastic 
pouch. The samples were checked for in vitro disintegration 
time and drug content for 30 days, 60 days and 90 days after 
storage33.
 
Table 10: Stability data of the optimized batch LT-6 batch 
Evaluation Parameter Duration 
0 days 30 days 60 days 90 days 
Disintegration Time (Sec) 30±0.37 30±0.27 30±0.87 30±0.07 
Drug Content (%) 99.42±0.39 99.15±0.45 99.12±0.67 99.10±0.81 
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DISCUSSION 
The solubility and dissolution rate of Lercanidipine 
hydrochloride has been improved by formulating a solid 
dispersion with PVP-K30 and Guargum in the preliminary 
screening for polymer (Batch LS-1 to LS-6).  Various natural 
and synthetic polymers are used in the preparation as they 
are economical, readily available, non-toxic, biodegradable 
and biocompatible. The solubility results are reported in 
table 1.  
After the preparation of solid dispersions, solubility 
determination is an important factor which affects the 
dissolution pattern. The solubility study confirmed that LS-5 
exhibited maximum solubility. Also it was revealed that 
Guargum showed much enhanced solubility as compared to 
other carrier. It was observed, that on increasing the 
polymer concentration, there was a sharp increase in 
solubility upto a point than further decreased, which can be 
attributed to the fact that as the polymer concentration 
increases, polymer gets adsorbs on the surface of drug, 
which retards the drug dissolution in the long run.  
The FTIR spectra of pure drug and solid dispersion batch LS-
5 displayed same characteristic peaks and revealed no 
chemical interaction between the drug and excipients as 
depicted in figure 1 and figure 2 respectively. Thermograms 
of drug and batch LS-5 are depicted in figure 3 and figure 4 
respectively. DSC reports also reveals that the disappearance 
of the drug melting peak is a result of amorphization as 
shown in figure 6. The reduction in drug peak height and its 
broadening can be considered as a result of the change in the 
crystalline state to amorphous one. SEM photographs are 
shown in figure 5 and figure 6.  
Optimization of independent variables outlined that solid 
dispersion prepared with drug: guargum (1:2 ratio) showed 
maximum solubility of  0.941±0.08 mg/ml. Based on this 
result, guargum polymer was selected for further 
formulation studies.  
Optimization of dependent variables, ANOVA was used for 
predicting the significance (p < 0.05) of the model and 
individual response parameters. The various plots were 
scrutinized to check the impact of independent factors on the 
measured responses. The quadratic model of F-value 27.45 
implies the model is significant p < 0.05. The contour plot 
and surface response plot in figure 7 showed the effect of 
different independent variables on solubility. The solubility 
of solid dispersion increased as the amount of guargum also 
increased, but to a certain level then decreased abruptly. 
Response 2 (% Drug release at time 60 mins Y2), After 
ANOVA estimation, the quadratic model of F-value 39.08 
implies the model is significant p < 0.0001. The various plots 
in figure 7 showed the effect of different independent 
variables on drug release at 60 min. The maximum drug 
release was obtained upto polymer concentration of 400 mg 
and further increase decreases the % drug release. This 
increase in rate of drug dissolution could be because of the 
dispersion of drug in pores of guargum and increased 
wettability. The dissolution rate showed a sharp rise at 1:2 
ratio, but then decreased at higher values. This is attributed 
to the fact that there is firm adsorption of the drug on 
polymer, which retards the dissolution process of the drug.  
Fast disintegrating tablets were prepared by direct 
compression method using optimized Lercanidipine Solid 
Dispersion (OSD-1), various super disintegrants 
crospovidone and croscarmellose are used and evaluated. 
Total of six formulations LT-1 – LT-6 with fixed 
concentration of different super disintegrants were prepared 
as shown in table 5. Weight variation for all batches was 
within the range prescribed for uncoated tablets. Friability 
was reported within 0.62 to 0.88% and hardness within 2.2 
to 3.0 kg/cm2 range. The wetting times and disintegration 
time was within 19 to 44 secs and 30 to 55 secs respectively. 
The accreditation for fast wettability and disintegration 
could be assigned to the capillary action mechanism of the 
superdisintegrant which leads to fast puffiness of the dosage 
form.  The drug content was found to be between 98 – 99 % 
which was within the acceptable limits. 
Among all formulations LT-6 showed maximum 97.6 % drug 
release within 10 min. This may be credited to the brisk 
dissolution of the tablet, which is due to the usage of super 
disintegrant and carrier all together in the formulations. The 
results showed that FDT formulated using croscarmellose 
sodium with concentration up to 6 % showed better results 
than FDT formulated with crospovidone. 
Finally LT-6 formulation was tested for stability at 
25°C/65% and 40oC/75% RH for a period of 3 months. The 
tablets were once more evaluated for drug content and in 
vitro disintegration time. At last, no modifications in the 
disintegration time and drug content of tablets were seen.  
CONCLUSION 
The above carried research work revealed that the solid 
dispersion technique could be a lucrative way for solubility 
enhancement of Lercanidipine hydrochloride, using Poly 
vinyl pyrollidine (PVP K-30) and guargum as carriers. From 
the preliminary screening for polymer, Guargum was 
selected for the further formulation studies. Optimized 
guargum solid dispersion was finally incorporated into FDT. 
The FDT were formulated by direct compression method, 
having crospovidone and croscarmellose as 
superdisintegrant. Batch LT-6 showed maximum 97.6 % 
drug release within 10 min. At last, it is summarised that fast 
disintegrating tablet formulation can be an innovative and 
promising approach for the delivery of Lercanidipine 
Hydrochloride with enhanced dissolution and bioavailability, 
and also as an effective therapy for the treatment of 
hypertension. 
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